Related references
Note: Only part of the references are listed.Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations
Igor Nudelman et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
Katharine Bushby et al.
LANCET NEUROLOGY (2010)
Brief Report: Dystrophin Immunity in Duchenne's Muscular Dystrophy.
Jerry R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Poly-L-aspartic Acid Enhances and Prolongs Gentamicin-mediated Suppression of the CFTR-G542X Mutation in a Cystic Fibrosis Mouse Model
Ming Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Nonaminoglycoside compounds induce readthrough of nonsense mutations
Liutao Du et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations
Igor Nudelman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
UTILITY OF CYSTATIN C TO MONITOR RENAL FUNCTION IN DUCHENNE MUSCULAR DYSTROPHY
Laurence Viollet et al.
MUSCLE & NERVE (2009)
RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology
Mohammad M. Ghahramani Seno et al.
HUMAN MOLECULAR GENETICS (2008)
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
Eitan Kerem et al.
LANCET (2008)
Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle
Annamaria De Luca et al.
NEUROBIOLOGY OF DISEASE (2008)
Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity
Hua Fan-Minogue et al.
RNA (2008)
Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human
Marcella Neri et al.
NEUROMUSCULAR DISORDERS (2007)
Aminoglycoside antibiotics: old drugs and new therapeutic approaches
T. Hermann
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
W. M. King et al.
NEUROLOGY (2007)
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers
Samit Hirawat et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin
Liat Linde et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model
Ming Du et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade
WD Biggar et al.
NEUROMUSCULAR DISORDERS (2006)
A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy
S Kimura et al.
BRAIN & DEVELOPMENT (2005)
Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment
L Bidou et al.
GENE THERAPY (2004)
Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: Total recovery after a treatment with the aminoglycoside gentamicin
L Loufrani et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice
M Arakawa et al.
JOURNAL OF BIOCHEMISTRY (2003)
Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle
P Dunant et al.
MUSCLE & NERVE (2003)
Rapid direct sequence analysis of the dystrophin gene
KM Flanigan et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Genetic susceptibility to aminoglycoside ototoxicity: How many are at risk?
HY Tang et al.
GENETICS IN MEDICINE (2002)
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene
M Du et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
SQ Harper et al.
NATURE MEDICINE (2002)
Diagnosis of Duchenne dystrophy by enhanced detection of small mutations
JR Mendell et al.
NEUROLOGY (2001)
Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy
M Sander et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy
A Ahmad et al.
HUMAN MOLECULAR GENETICS (2000)
Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system
M Manuvakhova et al.
RNA (2000)
Share Paper
